The study by Lassen et al. (2002) investigates the role of calcitonin gene-related peptide (CGRP) in migraine. CGRP is a peptide found in increased amounts during migraine attacks, but it is unclear whether this increase is a result of migraine or a cause. In a double-blind crossover study, 12 patients with migraine without aura received either human αCGRP (2 μg/min) or placebo intravenously for 20 minutes. The results showed that CGRP induced headache in almost all patients, with a median peak headache score of 1.0 during the infusion and 0 in the placebo group. After the infusion, all patients experienced headaches, with a median maximal headache score of 4 after CGRP and 0 after placebo. Three out of nine CGRP-treated patients developed delayed headaches that fulfilled the International Headache Society (IHS) criteria for migraine without aura. The study suggests that the increase in CGRP during migraine attacks may play a causative role in the development of migraine. The findings have implications for the development of CGRP antagonists as potential treatments for migraine.The study by Lassen et al. (2002) investigates the role of calcitonin gene-related peptide (CGRP) in migraine. CGRP is a peptide found in increased amounts during migraine attacks, but it is unclear whether this increase is a result of migraine or a cause. In a double-blind crossover study, 12 patients with migraine without aura received either human αCGRP (2 μg/min) or placebo intravenously for 20 minutes. The results showed that CGRP induced headache in almost all patients, with a median peak headache score of 1.0 during the infusion and 0 in the placebo group. After the infusion, all patients experienced headaches, with a median maximal headache score of 4 after CGRP and 0 after placebo. Three out of nine CGRP-treated patients developed delayed headaches that fulfilled the International Headache Society (IHS) criteria for migraine without aura. The study suggests that the increase in CGRP during migraine attacks may play a causative role in the development of migraine. The findings have implications for the development of CGRP antagonists as potential treatments for migraine.